article thumbnail

Inflation-Adjusted U.S. Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns

Drug Channels

It's time for Drug Channels annual examination of U.S. brand-name drug pricing. For 2024, average brand-name drugs list prices grew by only 2.3%. Whats more, after adjusting for overall inflation, brand-name drug net prices dropped for an unprecedented seventh consecutive year.

article thumbnail

ICYMI: Forget Foreign Price Controls: There’s a better solution to lowering drug prices

PhRMA

As the debate over drug pricing intensifies, some proposals—like the Most Favored Nation model—may sound appealing in theory, but they carry serious unintended consequences.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Inflation-Adjusted U.S. Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns (rerun)

Drug Channels

Click here to see the original post from January 2025. It's time for Drug Channels annual examination of U.S. brand-name drug pricing. For 2024, average brand-name drugs list prices grew by only 2.3%. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

article thumbnail

Why 2025 Will Be a Breakout Year for Pharma Marketing Innovation

Pharma Marketing Network

Pharma marketing innovation is poised for an unprecedented surge in 2025, driven by new technologies, regulatory shifts, and evolving patient expectations. This article dives deep into why 2025 will mark a pivotal moment for pharma marketing and how savvy brands can stay ahead.

article thumbnail

Third Circuit Affirms Rejection of AstraZeneca’s Challenges to IRA Drug Price Negotiation Program

Big Molecule Watch

On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district courts dismissal of AstraZenecas challenges to the Inflation Reduction Acts Drug Price Negotiation Program and CMSs Guidance implementing the Program.

article thumbnail

Changing the PAP Model

Pharmaceutical Commerce

24 Hours in the Hub Still Matters More Chris Dowd, ConnectiveRx June 16th 2025 Article Doubling down on patient access and support fundamentals will win out over Washington’s next move. Related Content Policy Whiplash?

article thumbnail

Pharma News Stories You Should Be Following

Pharma Marketing Network

Table of Contents Drug Approvals and Market Movers Digital Health and AI Integration Policy Changes and Global Regulations Marketing Trends in Pharma Advertising Drug Approvals and Market Movers Breakthrough therapies and new drug approvals regularly dominate pharma news. Why does this matter to marketers?